亚宝药业：盐酸普萘洛尔片通过仿制药一致性评价

Core Viewpoint - The announcement indicates that the company's subsidiary, Taiyuan Pharmaceutical, has received approval from the National Medical Products Administration for the supplement application of Propranolol Hydrochloride Tablets, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - The approved drug, Propranolol Hydrochloride Tablets, is expected to contribute to the company's revenue, as the domestic sales amount for this drug in 2023 is approximately 82.18 million RMB [1] - The public medical market accounts for about 57.76 million RMB of the total sales, while retail pharmacies contribute approximately 24.42 million RMB [1] - Currently, six other companies have also passed the consistency evaluation for this drug in the domestic market [1] Group 2: R&D Investment - The company has invested approximately 2.6005 million RMB in the research and development of this product [1]